Insider Monkey
Danaher Corporation (DHR) Maintains Buy Rating as Analysts See Upside in 2026
📈
AI Sentiment
Highly Positive
9/10
Danaher Corporation News
Latest updates and market news for DHR
11 news
Jan 13 - Jan 19, 2026
Page 1
MT Newswires
Leerink Partners Adjusts Price Target on Danaher to $270 From $260, Maintains Outperform Rating
📈
AI Sentiment
Highly Positive
8/10
Simply Wall St.
How Investors Are Reacting To Danaher (DHR) Upbeat 2025 Outlook And Growing Synthetic Biology Ambitions
📈
AI Sentiment
Highly Positive
8/10
Medical Device Network
JPM26: Danaher positioned to improve patient diagnostics
📈
AI Sentiment
Highly Positive
9/10
MT Newswires
Argus Adjusts Price Target on Danaher to $265 From $255, Maintains Buy Rating
📈
AI Sentiment
Highly Positive
8/10
Business Wire
Integrated DNA Technologies Expands Synthetic Biology Portfolio with Ansa Biotechnologies’ Clonal DNA and XL Clonal DNA Products
📈
AI Sentiment
Highly Positive
9/10
Share this news page